<DOC>
	<DOCNO>NCT01243281</DOCNO>
	<brief_summary>The outcome treatment chronic hepatitis B determine viral host interaction , thus combination therapy immunomodulator ( PEG-IFN ) potent antiviral drug ( entecavir ) improve response rate . In addition , simultaneous assessment viral host genetic factor associate SVR may help identify predictor treatment outcome , turn significant reduce cost/effect therapy</brief_summary>
	<brief_title>Pegylated Interferon Alpha-2b Monotherapy Versus Combination With Entecavir HBeAg-negative Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Men woman 18 65 year age Patients HBeAgnegative chronic hepatitis B Positive HBsAg least 6 month , negative antiHBs HBeAg Serum HBV DNA level â‰¥ 2,000 IU/mL screening Increased alanine aminotransferase ( ALT ) level [ great upper limit normal ( ULN ) less 10xULN } No sign symptom advance liver disease Patient liver biopsy within 1 year screen Patient previous treatment IFN , pegIFN , and/or entecavir Patient evidence history chronic hepatitis cause HBV , include limited nonalcoholic steatohepatitis ( NASH ) , druginduced hepatitis , autoimmune hepatitis Patient coinfection hepatitis C virus and/or human immunodeficiency virus Patients liver cancer Female patient pregnant , lactating , expect conceive donate egg , childbearing potential throughout treatment . Patient condition contraindicate treatment PEGIFN entecavir Patient condition prestudy laboratory abnormality , history illness , opinion investigator , might confound result study pose additional risk administer study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>hepatitis B</keyword>
	<keyword>HBeAg</keyword>
	<keyword>pegylated interferon</keyword>
	<keyword>entecavir</keyword>
</DOC>